Atomoxetine is the most prescribed non-stimulant ADHD medication in the UK and the usual first-line option when stimulants are not suitable [1, 2]. This article explains how atomoxetine works, who it tends to suit, what a slower onset of action means in practice, and the side-effect profile to plan around.
What atomoxetine is
Atomoxetine is sold under the brand name Strattera in the UK and is also available as generic atomoxetine [2]. It is a selective noradrenaline reuptake inhibitor. The mechanism is narrower than that of stimulants: atomoxetine blocks the noradrenaline transporter, which keeps noradrenaline available in the synapse, particularly in the prefrontal cortex. Through downstream signalling, it also increases dopamine availability in the prefrontal cortex but not in the striatum or nucleus accumbens, which is part of why it does not carry the same abuse-potential profile as stimulants [2].
Atomoxetine is not a controlled drug, which has practical implications: prescriptions can be written for longer periods, can include repeats, and it travels more easily across international borders than a Schedule 2 stimulant.
It is licensed in the UK from age 6 for ADHD and continues into adult treatment [2]. Under NICE NG87, atomoxetine is offered as an alternative when stimulants are ineffective or not tolerated, or where there are reasons stimulants are unsuitable [1].
When atomoxetine is the right fit
Several clinical situations make atomoxetine a sensible first or second medication choice [1, 2]:
- A history of stimulant intolerance, including significant anxiety, mood disturbance, or cardiovascular effects on stimulants
- Co-occurring tic disorders where stimulants have worsened tics
- A history of substance use disorder where a non-controlled-drug option is preferable
- Significant anxiety that responds to atomoxetine; some patients with ADHD and co-occurring generalised anxiety report dual benefit
- Patient preference, particularly where the controlled-drug prescribing route is a barrier
- Settings where the controlled-drug regulations make stimulant supply difficult (some shared-living settings, certain travel patterns)
Atomoxetine is not "weaker" than a stimulant in a meaningful clinical sense; it is differently sized and slower to take effect. The Cortese 2018 network meta-analysis ranked atomoxetine below stimulants for efficacy at the group level, but for individual patients who do not tolerate stimulants, atomoxetine often produces meaningful benefit [4].
What atomoxetine treatment looks like
The most important difference between atomoxetine and stimulants is the timeframe over which benefit emerges.
Stimulants act within hours, often within minutes; atomoxetine acts across weeks. The BNF notes that the full clinical effect of atomoxetine typically requires four to eight weeks of continuous treatment, sometimes longer [2]. This has direct practical consequences:
- Patients should not stop atomoxetine in the first week because they do not feel anything. The medication is working in the background.
- Side effects in the first one to two weeks are common but tend to settle.
- Dose adjustments need a settling period before their effect can be judged, so titration is slower than with stimulants.
Atomoxetine is taken once daily or, in some cases, split between morning and evening doses to manage early side effects. It can be taken with or without food. Missing the occasional dose has less impact than with a stimulant because the effect is cumulative, but consistency still matters.
Common side effects
The BNF and BNFc list the common adverse effects of atomoxetine [2, 3]. They include:
- Nausea, particularly in the first one to two weeks
- Reduced appetite
- Dry mouth
- Constipation
- Fatigue or sedation early in treatment, sometimes followed by improved energy as the effect emerges
- A small rise in resting heart rate and blood pressure
- Sleep disturbance, including either insomnia or daytime sleepiness depending on timing
- Mood changes, including emotional flatness in some patients
- Sexual dysfunction in adults
- In children, slowed growth in weight; height usually less affected than with stimulants [3]
Most early effects settle within two to four weeks. Persistent or significant effects warrant a conversation with the prescriber and may prompt a dose adjustment, a dose-split (morning and evening), or a switch.
Safety considerations
Atomoxetine carries an MHRA-flagged caution about suicidal thoughts, particularly in children and adolescents [5]. The absolute risk is low, but parents and patients are asked to report any new or worsening suicidal thinking, mood changes, agitation, or self-harm immediately. Routine monitoring at the start of treatment includes mood as well as the usual cardiovascular measurements.
Pre-treatment monitoring under NICE NG87 includes blood pressure and heart rate, weight and height (in children), and review of any cardiac or hepatic history [1]. Atomoxetine can rarely cause hepatic dysfunction; jaundice or unusual fatigue should prompt urgent review and liver function tests [2].
Routine follow-up monitoring includes:
- Blood pressure and heart rate at each review
- Weight and growth measurements in children
- Mood, particularly during the first three months
- Sleep, appetite and bowel habit
Where atomoxetine sits in the pathway
NICE NG87 sets the order as stimulants first, atomoxetine second, guanfacine third for children and adolescents, with the order more flexible in adults [1]. In practice, atomoxetine is often chosen as the first medication where stimulants are unsuitable, or as the second medication when stimulants have been tried and not worked. The choice between atomoxetine and guanfacine as the next step depends on age, side-effect profile and co-occurring conditions; the rationale is covered in the ADHD medication and titration with NeuroFX pathway alongside the stimulant options.
A combination of atomoxetine and a stimulant is sometimes used where partial response to either alone is not enough. This is a specialist decision and not appropriate without specific clinical justification.
Practical notes
- Atomoxetine is not a controlled drug. Prescriptions can be written with repeats and are not subject to the 28-day quantity limits that apply to Schedule 2 stimulants.
- The capsules should not be opened. If swallowing is a difficulty, ask the prescriber rather than splitting; the contents of the capsule are irritant to the eyes [2].
- Atomoxetine can interact with certain antidepressants, particularly some SSRIs that inhibit CYP2D6, raising atomoxetine levels. Tell the prescriber every medication, supplement and over-the-counter product you take.
- Stopping atomoxetine does not require tapering in most cases, but speak to the prescriber rather than stopping abruptly.
- Effect persists 24 hours from a single dose, so a single missed dose is rarely a problem; chronic missed doses undo the benefit.
What this means in practice
- Atomoxetine is the most prescribed non-stimulant in UK ADHD treatment and the usual first-line non-stimulant.
- It works on noradrenaline (and indirectly on prefrontal dopamine), so the mechanism is narrower than stimulants but the clinical benefit can be significant.
- Effect builds over four to eight weeks rather than within hours. Patience in the early weeks is essential.
- It is not a controlled drug, which is a practical advantage for some patients.
- New or worsening suicidal thinking, agitation, or significant mood change is a reason to contact the prescriber urgently.
When to speak to a professional
Speak to your GP, your prescriber or NHS 111 if a new symptom worries you, if your blood pressure or heart rate feels noticeably different, or if you notice changes in mood that concern you. Seek urgent help via 999 or A&E for chest pain, shortness of breath, jaundice, or any acute mental health crisis including thoughts of self-harm. NeuroFX offers private adult ADHD assessment and paediatric ADHD assessment for children aged 6 and upwards, including specialist initiation of atomoxetine where appropriate.
Sources
- NICE. Attention deficit hyperactivity disorder: diagnosis and management. NG87. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng87
- British National Formulary. Atomoxetine. https://bnf.nice.org.uk/drugs/atomoxetine/
- British National Formulary for Children. Atomoxetine. https://bnfc.nice.org.uk/drugs/atomoxetine/
- Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit/hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738.
- Medicines and Healthcare products Regulatory Agency. Drug Safety Update: atomoxetine and suicidal thoughts. https://www.gov.uk/drug-safety-update
